Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Consulting agrmnt Appointed director CC transcript Inv. presentation Acq. announced Appointed CFO
|
Innoviva, Inc. (INVA)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/11/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
05/15/2023 |
SC 13D/A
| Sarissa Capital Management LP reports a 10.5% stake in Innoviva, Inc. |
01/10/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
07/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/23/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
04/01/2022 |
SC 13D/A
| Innoviva, Inc. reports a 80.1% stake in ARMATA PHARMACEUTICALS, INC. |
03/15/2022 |
SC 13D/A
| Innoviva, Inc. reports a 74.9% stake in ENTASIS THERAPEUTICS HOLDINGS INC. |
02/18/2022 |
SC 13D/A
| Innoviva, Inc. reports a 75.2% stake in ENTASIS THERAPEUTICS HOLDINGS INC. |
02/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/01/2022 |
SC 13D/A
| Innoviva, Inc. reports a 75.2% stake in ENTASIS THERAPEUTICS HOLDINGS INC. |
11/01/2021 |
SC 13D/A
| Innoviva, Inc. reports a 73.8% stake in ARMATA PHARMACEUTICALS, INC. |
06/11/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/25/2021 |
SC 13D/A
| Sarissa Capital Management LP reports a 9.2% stake in Innoviva, Inc. |
05/25/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/03/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
04/05/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/17/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/12/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
01/27/2021 |
SC 13D/A
| Innoviva, Inc. reports a 68% stake in ARMATA PHARMACEUTICALS, INC. |
12/14/2020 |
SC 13D/A
| Sarissa Capital Management LP reports a 6.3% stake in Innoviva, Inc. |
09/01/2020 |
SC 13D/A
| Innoviva, Inc. reports a 69% stake in ENTASIS THERAPEUTICS HOLDINGS INC. |
08/31/2020 |
SC 13D/A
| Innoviva, Inc. reports a 67.8% stake in ENTASIS THERAPEUTICS HOLDINGS INC. |
06/12/2020 |
SC 13D/A
| Innoviva, Inc. reports a 67.8% stake in ENTASIS THERAPEUTICS HOLDINGS INC. |
03/31/2020 |
SC 13D/A
| Innoviva, Inc. reports a 63.7% stake in ARMATA PHARMACEUTICALS, INC. |
04/10/2018 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 31.4% stake in INNOVIVA, INC. |
04/13/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
08/25/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
08/01/2013 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
05/16/2012 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
04/02/2012 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
|
|